Scott Gettinger, MD
Professor of Internal Medicine (Medical Oncology)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Chief, Thoracic Medical Oncology
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Chief, Thoracic Medical Oncology
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Chief, Thoracic Medical Oncology
Contact Info
About
Copy Link
Titles
Professor of Internal Medicine (Medical Oncology)
Chief, Thoracic Medical Oncology
Biography
Dr. Gettinger is internationally recognized for his expertise in lung cancer treatment and research. He is best known for his work in immunotherapy and targeted therapy for non-small cell lung cancer. He currently leads several clinical trials evaluating novel therapies for patients with lung cancer. His primary translational research interests include understanding mechanisms of sensitivity and resistance to molecularly targeted therapies and immunotherapies.
Last Updated on April 07, 2025.
Appointments
Medical Oncology and Hematology
ProfessorPrimary
Other Departments & Organizations
- Center for Thoracic Cancers
- Developmental Therapeutics
- Internal Medicine
- Medical Oncology and Hematology
- SPORE in Lung Cancer
- Yale Cancer Center
- Yale Medicine
- Yale New Haven Health System
- Yale Ventures
Education & Training
- Fellow
- Beth Israel Medical Center, NY (2005)
- Resident
- Beth Israel Medical Center, NY (2002)
- MD
- Brooklyn College (1999)
- BS
- Trinity College (1991)
Research
Copy Link
Overview
Medical Research Interests
Carcinoma, Non-Small-Cell Lung; Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Immunotherapy; Lung; Medical Oncology; Thoracic Neoplasms; Translational Research, Biomedical
ORCID
0000-0003-0886-6880
Research at a Glance
Yale Co-Authors
Frequent collaborators of Scott Gettinger's published research.
Publications Timeline
A big-picture view of Scott Gettinger's research output by year.
Research Interests
Research topics Scott Gettinger is interested in exploring.
Roy S. Herbst, MD, PhD
David Rimm, MD, PhD
Anna Wurtz
Harriet Kluger, MD
Mario Sznol, MD
Veronica Chiang, MD, FAANS
147Publications
56,893Citations
Carcinoma, Non-Small-Cell Lung
Immunotherapy
Medical Oncology
Lung
Thoracic Neoplasms
Translational Research, Biomedical
Publications
2026
PD-L1 PET/CT imaging with 18F-BMS-986,229 and 18F-BMS-986,192 in patients with advanced-stage non-small cell lung cancer
Smit J, Borm F, Gerards N, Wiegers S, Holden D, Leung D, Grootendorst D, Windhorst B, Nabulsi N, Cai Z, Huang Y, Carson R, Gettinger S, Smit E, Boellaard R, de Langen A. PD-L1 PET/CT imaging with 18F-BMS-986,229 and 18F-BMS-986,192 in patients with advanced-stage non-small cell lung cancer. European Journal Of Nuclear Medicine And Molecular Imaging 2026, 1-10. PMID: 42809016, DOI: 10.1007/s00259-026-08188-4.Peer-Reviewed Original ResearchFast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)
He K, Forde P, Govindan R, Santoro A, Gettinger S, Borghaei H, Spira A, Chu Q, Zinner R, Schoenfeld A, Camidge D, Spigel D, Gurpide A, Juergens R, Laurie S, Cerra M, Spires T, Greenawalt D, Rapoport I, Gainor J. Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung). ESMO Open 2026, 11: 106078. PMID: 41702354, PMCID: PMC12925557, DOI: 10.1016/j.esmoop.2026.106078.Peer-Reviewed Original ResearchCitationsAltmetric
2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity
Cortellini A, Garbo E, La Cava G, Citarella F, Santo V, Brunetti L, Pinato D, Naidoo J, Loza M, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Montrone M, Owen D, Signorelli D, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Yendamuri S, Grossi F, Josephides E, Tomasik B, Giusti R, Bria E, Sebastian M, Rost M, Acker F, Landi L, Mazzoni F, Morabito A, Leonetti A, Cantini L, Mountzios G, Kalvapudi S, O'Reilly D, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Piedra A, Cortinovis D, Tonini G, Minuti G, Mezquita L, Gorria T, Beninato T, Lo Russo G, PrelaJ A, De Giglio A, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Abu Hejleh T, Takada K, Naqash A, Garassino M, Wakelee H, Nassar A, Ricciuti B, Soda P, Caruso C, Guarrasi V. Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. Lung Cancer 2025, 209: 108799. PMID: 41108882, DOI: 10.1016/j.lungcan.2025.108799.Peer-Reviewed Original ResearchCitationsAltmetricTransformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Cortellini A, Santo V, Brunetti L, Garbo E, Pinato D, La Cava G, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Alessi J, Montrone M, Owen D, Ramella S, Signorelli D, Fidler M, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, D’Alessio A, Banna G, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Balachandran K, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Sforza V, Tiseo M, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Fitzpatrick O, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Piedra A, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Prelaj A, De Giglio A, Rogado J, Moliner L, Nadal E, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B, Soda P, Caruso C, Guarrasi V. Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e012423. PMID: 41022528, PMCID: PMC12481261, DOI: 10.1136/jitc-2025-012423.Peer-Reviewed Original ResearchCitationsAltmetricActivity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status
Bazhenova L, Hodgson J, Camidge D, Langer C, Huber R, Kim D, Reckamp K, Ahn M, Tan D, Patel J, Vincent S, Li C, Humphries M, Zhang P, Rivera V, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clinical Lung Cancer 2025, 26: e503-e513.e11. PMID: 40582920, DOI: 10.1016/j.cllc.2025.05.016.Peer-Reviewed Original ResearchCitationsAltmetricDeterminants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi J, Montrone M, Owen D, Signorelli D, Fidler M, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika N, Napolitano A, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Rogado J, Moliner L, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Torri V, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e010674. PMID: 39904562, PMCID: PMC11795382, DOI: 10.1136/jitc-2024-010674.Peer-Reviewed Original ResearchCitationsAltmetric
2024
Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Gettinger S, Song Z, Reckamp K, Moscow J, Gray R, Wang V, McShane L, Rubinstein L, Patton D, Williams P, Hamilton S, Kong X, Tricoli J, Conley B, Arteaga C, Harris L, O'Dwyer P, Chen A, Flaherty K. Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. JCO Precision Oncology 2024, 8: e2300725. PMID: 38986051, PMCID: PMC13371943, DOI: 10.1200/po.23.00725.Peer-Reviewed Original ResearchCitationsLifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
Schoenfeld A, Lee S, de Spéville B, Gettinger S, Häfliger S, Sukari A, Papa S, Rodríguez-Moreno J, Finckenstein F, Fiaz R, Catlett M, Chen G, Qi R, Masteller E, Gontcharova V, He K. Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer Discovery 2024, 14: 1389-1402. PMID: 38563600, PMCID: PMC11294887, DOI: 10.1158/2159-8290.cd-23-1334.Peer-Reviewed Original ResearchCitationsAltmetricASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Hu B, Wiesehofer M, de Miguel F, Liu Z, Chan L, Choi J, Melnick M, Estape A, Walther Z, Zhao D, Lopez-Giraldez F, Wurtz A, Cai G, Fan R, Gettinger S, Xiao A, Yan Q, Homer R, Nguyen D, Politi K. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts. Cancer Research 2024, 84: 1303-1319. PMID: 38359163, PMCID: PMC11142404, DOI: 10.1158/0008-5472.can-23-0438.Peer-Reviewed Original ResearchCitationsAltmetricMulti-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial
Parra E, Zhang J, Duose D, Gonzalez-Kozlova E, Redman M, Chen H, Manyam G, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli M, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang H, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray J, Herbst R, Wistuba I, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee J, Zhang J, Haymaker C. Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial. Clinical Cancer Research 2024, 30: 1655-1668. PMID: 38277235, PMCID: PMC11016892, DOI: 10.1158/1078-0432.ccr-23-0251.Peer-Reviewed Original ResearchCitationsAltmetric
Clinical Trials
Current Trials
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
IRB ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsLUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
IRB ID2000025282RoleSub InvestigatorPrimary Completion Date01/28/2029Recruiting ParticipantsIntegration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
IRB ID2000028827RoleSub InvestigatorPrimary Completion Date12/15/2024Recruiting ParticipantsDetermining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer
IRB ID1603017333RolePrincipal InvestigatorPrimary Completion Date06/16/2036Recruiting Participants
Clinical Care
Copy Link
Overview
Scott Gettinger, MD, is a medical oncologist who specializes in lung cancer treatment and research.
He says the best part of his job is the ability to provide the latest advances in treatment to his patients, many of whom have complicated cases and require care from multiple specialists.
Dr. Gettinger leads several clinical trials evaluating novel therapies for patients with lung cancer. His primary interests include understanding mechanisms of sensitivity and resistance to molecularly targeted therapies and immunotherapies for non-small cell lung cancer.
“Treatment for lung cancer is constantly evolving and new treatments are available to target specific tumors,” he says. “There is always something we can offer that will help.”
Clinical Specialties
Thoracic Oncology; Medical Oncology
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
News
- November 18, 2025
Progress and Hope: Sharing the Latest Advances in Lung Cancer Care
- November 12, 2025
Twenty-Seven YSM Faculty Members Recognized for Highly Cited Research
- May 30, 2025Source: Yale Medicine
How Smilow Doctors Are Saving My Life: A Cancer Survivor’s Story
- November 14, 2024
Understanding Lung Cancer: A Conference to Raise Awareness and Offer Hope to Those Impacted by Lung Cancer
Get In Touch
Copy Link
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.